Melissa Velez
Physician Assistant · Brooklyn, NYNPI 1639392855
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. EMD Serono, Inc. accounts for 83.3% of it on its own, with 36 other manufacturers making up the rest. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 485 payments — averaging $139.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$56K
- Biogen$3K
- Abbott$1K
- TG Therapeutics, Inc.$994
- Bristol Myers Squibb$809
- MDD US Operations, LLC$754
- plus $4K from 31 others
What the payments were for
- Consulting fees$2,9404%
- Speaking & faculty fees$40,41260%
- Travel & lodging$9,79714%
- Food & beverage$14,28221%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 116 | $56,297 |
| Biogen | 86 | $2,755 |
| Abbott | 10 | $1,498 |
| TG Therapeutics, Inc. | 19 | $994 |
| Bristol Myers Squibb | 35 | $809 |
| MDD US Operations, LLC | 27 | $754 |
| AbbVie(2 entities) | 40 | $732 |
| Novartis | 12 | $458 |
| Alnylam Pharmaceuticals Inc. | 25 | $422 |
| Eisai Inc. | 20 | $362 |
| Teva Pharmaceuticals USA, Inc. | 11 | $351 |
| AstraZeneca | 11 | $328 |
| Grifols USA, LLC | 7 | $183 |
| Argenx US, Inc. | 6 | $169 |
| Genentech USA, Inc. | 5 | $132 |
| Acadia Pharmaceuticals Inc | 5 | $131 |
| Merz Pharmaceuticals, LLC | 6 | $128 |
| Otsuka America Pharmaceutical, Inc. | 5 | $125 |
| Lundbeck LLC | 5 | $121 |
| Sanofi | 3 | $118 |
| SK Life Science, Inc. | 4 | $110 |
| Xeris Pharmaceuticals, Inc. | 4 | $98 |
| Amgen | 5 | $96 |
| Pfizer | 3 | $71 |
| Kyowa Kirin, Inc. | 2 | $48 |
| UCB, Inc. | 2 | $45 |
| Boston Scientific | 1 | $30 |
| Neurelis, Inc. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Life Molecular Imaging Ltd | 1 | $25 |
| CSL Behring | 1 | $25 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Acera Surgical, Inc. | 1 | $23 |
| Avion Pharmaceuticals | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,605 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 32 | $293,681 |
| BetaseronInterferon Beta-1b | 27 | $261,473 |
| ZeposiaOzanimod Hydrochloride | 17 | $142,624 |
| Kesimpta PenOfatumumab | 14 | $141,873 |
| Glatiramer Acetate | 13 | $38,178 |
| Dimethyl Fumarate | 19 | $38,172 |
| Dalfampridine ErDalfampridine | 57 | $25,023 |
| NeuproRotigotine | 12 | $9,821 |
| Pregabalin | 25 | $2,406 |
| Gabapentin | 96 | $1,310 |
| Baclofen | 88 | $1,137 |
| Quetiapine Fumarate | 47 | $745 |
| Duloxetine Hcl | 58 | $694 |
| Nortriptyline Hcl | 35 | $493 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $2,755 | $293,68132 claims |
| UCB, Inc.Neupro | $45 | $9,82112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Brooklyn
- Kaitlyn NelsonBrooklyn$289K
- Steven KongBrooklyn$66K
- Hong ChenBrooklyn$57K
- Lindsey AxtBrooklyn$52K
- Gregory CelestinBrooklyn$41K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.